Literature DB >> 26630591

Medicine: Expanding possibilities.

Virginia Gewin.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26630591     DOI: 10.1038/528S10a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  5 in total

1.  Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9.

Authors:  Pankaj K Mandal; Leonardo M R Ferreira; Ryan Collins; Torsten B Meissner; Christian L Boutwell; Max Friesen; Vladimir Vrbanac; Brian S Garrison; Alexei Stortchevoi; David Bryder; Kiran Musunuru; Harrison Brand; Andrew M Tager; Todd M Allen; Michael E Talkowski; Derrick J Rossi; Chad A Cowan
Journal:  Cell Stem Cell       Date:  2014-11-06       Impact factor: 24.633

Review 2.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.

Authors:  Thomas Gaj; Charles A Gersbach; Carlos F Barbas
Journal:  Trends Biotechnol       Date:  2013-05-09       Impact factor: 19.536

3.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype.

Authors:  Hao Yin; Wen Xue; Sidi Chen; Roman L Bogorad; Eric Benedetti; Markus Grompe; Victor Koteliansky; Phillip A Sharp; Tyler Jacks; Daniel G Anderson
Journal:  Nat Biotechnol       Date:  2014-03-30       Impact factor: 54.908

4.  BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis.

Authors:  Matthew C Canver; Elenoe C Smith; Falak Sher; Luca Pinello; Neville E Sanjana; Ophir Shalem; Diane D Chen; Patrick G Schupp; Divya S Vinjamur; Sara P Garcia; Sidinh Luc; Ryo Kurita; Yukio Nakamura; Yuko Fujiwara; Takahiro Maeda; Guo-Cheng Yuan; Feng Zhang; Stuart H Orkin; Daniel E Bauer
Journal:  Nature       Date:  2015-09-16       Impact factor: 49.962

5.  CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting.

Authors:  D G Courtney; J E Moore; S D Atkinson; E Maurizi; E H A Allen; D M L Pedrioli; W H I McLean; M A Nesbit; C B T Moore
Journal:  Gene Ther       Date:  2015-08-20       Impact factor: 5.250

  5 in total
  1 in total

Review 1.  CRISPR-Cas9 technology and its application in haematological disorders.

Authors:  Han Zhang; Nami McCarty
Journal:  Br J Haematol       Date:  2016-09-13       Impact factor: 6.998

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.